Latest stories on VTGN
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
Yahoo Finance38 · neutralproduct/pr
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Seeking Alpha56 · neutralproduct/pr
This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell
Stocktwits News38 · neutralproduct/pr
VistaGen pivots fasedienol toward long-term anxiety treatment
TipRanks56 · neutralproduct/pr
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth
TipRanks34 · bearishgeneral
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | VTGN Stock News
StockTitan56 · neutralearnings
VistaGen Reaches Key Safety Milestone for Fasedienol Program
TipRanks63 · neutralproduct/pr
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
PR Newswire34 · bearishgeneral
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference | VTGN Stock News
StockTitan56 · neutralgeneral